Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Christiansson, Lisa ^a   Söderlund, Stina ^b   Svensson, Emma ^a   Mustjoki, Satu ^c   Bengtsson, Mats ^a,b   Simonsson, Bengt ^b   Olsson Strömberg, Ulla ^b   Loskog, Angelica S I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD34 ANTIGEN; HYDROXYUREA; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; SOLUBLE CD25 ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INHIBITION; CELL CLONE; CELL COUNT; CELL LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LOW RISK POPULATION; LYMPHOCYTE PROLIFERATION; MALE; MYELOID DERIVED SUPPRESSOR CELL; PROTEIN EXPRESSION; SUPPRESSOR CELL; SWEDEN; T LYMPHOCYTE; UPREGULATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD274; ANTIGENS, CD34; ARGINASE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELOID CELLS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84873192230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055818     Document Type: Article

References (54)

1. Rowley JD, (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293.
2. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, et al. (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63: 789-799.
3. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, et al. (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23: 1054-1061.
4. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-562.
5. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, et al. (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101: 441-445.
6. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, et al. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029-1035.
7. Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, et al. (2011) Combination of pegylated IFN-{alpha}2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118: 3228-3235.
8. Li Z, Qiao Y, Liu B, Laska EJ, Chakravarthi P, et al. (2005) Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 11: 4460-4468.
9. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, et al. (2011) Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29: 1634-1642.
10. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, et al. (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363: 2511-2521.
11. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, et al. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678-689.
12. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R, (2010) Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70: 4335-4345.
13. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, et al. (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14: 8270-8278.
14. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, et al. (2011) Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13: 591-599.
15. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI, (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172: 989-999.
16. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P, (2003) L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24: 302-306.
17. Rodriguez PC, Quiceno DG, Ochoa AC, (2007) L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109: 1568-1573.
18. Gross S, Walden P, (2008) Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Immunol Lett 116: 7-14.
19. Rowe JH, Johanns TM, Ertelt JM, Way SS, (2008) PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes. J Immunol 180: 7553-7557.
20. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF, (2009) Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114: 1528-1536.
21. Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Stromberg U, et al. (2010) T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 131: 371-376.
22. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, et al. (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172-3177.
23. Perez-Encinas M, Villamayor M, Campos A, Gonzalez S, Bello JL, (1998) Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma. Haematologica 83: 752-754.
24. Mustjoki S, Rohon P, Rapakko K, Jalkanen S, Koskenvesa P, et al. (2010) Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy. Leukemia 24: 219-222.
25. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, et al. (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118: 686-692.
26. Jiao ZJ, Gao JJ, Hua SH, Chen DY, Wang WH, et al. (2012) Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer. World J Gastroenterol 18: 5454-5461.
27. El-Hady SB, Farahat MH, Atfy M, Elhady MA, (2012) Nitric oxide metabolites and arginase I levels in beta-thalassemic patients: an Egyptian study. Ann Hematol 91: 1193-1200.
28. Eleftheriadis T, Yiannaki E, Antoniadi G, Liakopoulos V, Pissas G, et al. (2012) Plasma indoleamine 2,3-dioxygenase and arginase type I may contribute to decreased blood T-cell count in hemodialysis patients. Ren Fail 34: 1118-1122.
29. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW, (2011) Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother.
30. Chen X, Liu S, Wang L, Zhang W, Ji Y, et al. (2008) Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther 7: 622-627.
31. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, et al. (2009) IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 182: 6562-6568.
32. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, et al. (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135: 234-243.
33. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, et al. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58: 49-59.
34. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, et al. (2010) Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 16: 1812-1823.
35. Leu SY, Wang SR, (1992) Clinical significance of arginase in colorectal cancer. Cancer 70: 733-736.
36. Fife BT, Pauken KE, (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci 1217: 45-59.
37. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
38. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465.
39. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, et al. (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175.
40. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, et al. (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14: 3044-3051.
41. Loos M, Langer R, Schuster T, Gertler R, Walch A, et al. (2011) Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma. Ann Thorac Surg 91: 1025-1031.
42. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, et al. (2011) PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128: 887-896.
43. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, et al. (2011) Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117: 2192-2201.
44. Salih HR, Wintterle S, Krusch M, Kroner A, Huang YH, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol 34: 888-894.
45. Riley JL, (2009) PD-1 signaling in primary T cells. Immunol Rev 229: 114-125.
46. Rubin LA, Jay G, Nelson DL, (1986) The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 137: 3841-3844.
47. Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, et al. (2005) Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 130: 709-715.
48. Motoi T, Uchiyama T, Hori T, Itoh K, Uchino H, et al. (1989) Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood 74: 1052-1057.
49. Gause A, Jung W, Schmits R, Tschiersch A, Scholz R, et al. (1992) Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. Ann Oncol 3 Suppl 4: 49-52.
50. Kawatani T, Endo A, Tajima F, Ooi S, Kawasaki H, (1997) Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders. Int J Hematol 65: 123-128.
51. Kitagawa J, Hara T, Tsurumi H, Goto N, Kanemura N, et al. (2009) Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol 135: 53-59.
52. Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, et al. (2009) Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 20: 526-533.
53. Herrmann H, Sadovnik I, Cerny-Reiterer S, Blatt K, Ghanim V, et al. (2011) The Leukemic Stem Cell (LSC) in Ph+ CML Is a CD34+/CD38-/Lin- Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1{alpha}. ASH Annual Meeting Abstracts 118: 961-.
54. Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM, et al. (2005) Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 90: 1315-1323.